Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.
Recruiting now · Phase 3
Conditions studied: Hereditary Spastic Paraplegia Type 50
In brief
Phase 3, open-label study to assess the efficacy and safety of a single lumbar intrathecal administration of MELPIDA in individuals with Hereditary Spastic Paraplegia Type 50 (SPG50).
Key facts
- Study ID
- NCT06692712
- Run by
- Elpida Therapeutics SPC
- People needed
- 24
- Starts
- 2026-04-01
- Expected to finish
- 2032-06-01
- Last updated by the study team
- 2026-04-20
Who can join
Age: 0 and older, up to 6. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Texas Southwestern Medical Center — Dallas, Texas, United States (enrolling)
- Sant Joan de Deu — Barcelona, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.